China's national drug regulator approved Luye Pharma Group's (HKG:2186) Investigational New Drug application for its anti-depression drug LY03021, according to a Monday filing with the Hong Kong bourse.
The medication inhibits the norepinephrine transporter (NET), the dopamine transporter (DAT), and gamma-aminobutyric acid type A receptor-positive allosteric modulator (GABAAR PAM), controlling depression, according to the filing.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。